MS Research Spotlight: Young Donor Blood Scam, MS Dementia, & More
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The MultipleSclerosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Bellamy, J. “Young blood” infusions: same old snake oil”. Science-Based Medicine. June 20, 2019. https://sciencebasedmedicine.org/young-blood-infusions-same-old-snake-oil/.
- Important Information about Young Donor Plasma Infusions for Profit. Food and Drug Administration (FDA). February 19, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-about-young-donor-plasma-infusions-profit
- Katsari, M., Dimitrios K. et al. “Does multiple sclerosis cause progressive and widespread cognitive decline?” “Does multiple sclerosis cause progressive and widespread cognitive decline?” June 10, 2019. https://www.obrela-journal.gr/index.php/obrela/article/view/117/136
- MS Trial Alert: Seeking People with Relapsing MS Who Have Never Taken a Disease-Modifying Therapy for Trial of Treatment Strategies to Prevent Disability. National Multiple Sclerosis Society. June 7, 2019. https://www.nationalmssociety.org/About-the-Society/News/MS-Trial-Alert-Seeking-People-with-Relapsing-MS-Wh
- US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis. Business Wire. June 6, 2019. https://www.businesswire.com/news/home/20190606005133/en/.
- George, J. African-American MS Patients Assessed in Real-World Tecfidera Study—ESTEEM looks at safety and efficacy of dimethyl fumarate. MedPage Today. June 3, 2019. https://www.medpagetoday.com/meetingcoverage/cmsc/80216